美国阿尔茨海默病III期临床试验的种族和民族报告和代表性

Zhuoer Lin, Ruochen Sun, Joseph S Ross, Kien Lau, Sophia Stumpf, Xi Chen
{"title":"美国阿尔茨海默病III期临床试验的种族和民族报告和代表性","authors":"Zhuoer Lin, Ruochen Sun, Joseph S Ross, Kien Lau, Sophia Stumpf, Xi Chen","doi":"10.1101/2025.05.03.25326933","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) disproportionately affects racial and ethnic minoritized populations in the United States, yet these groups remain markedly underrepresented in clinical research. Phase III clinical trials are critical for informing regulatory decision and treatment guidelines, but the extent to which they report and include racial and ethnic diverse participants in the US context has not been systematically assessed.</p><p><strong>Methods: </strong>We conducted a comprehensive retrospective review of all US-based Phase III AD clinical trials from 1997 to 2023 using the Trialtrove database, cross-referenced with PubMed, ClinicalTrials.gov, and other public sources. We analyzed long-term trends in the reporting and representation of racial and ethnic groups across the longest observation period to date.</p><p><strong>Results: </strong>Of 88 identified trials, 71 (80.7%) had published data. Nearly half (49.3%) did not report any race or ethnicity information. Among those that did, most focused on White patients, with limited and inconsistent reporting for racial and ethnic minoritized groups. Median enrollment was 0.9% for Asian or Pacific Islander, 4.5% for Black (ethnicity unspecified), 7.2% for Black (non-Hispanic), 5.2% for Hispanic, and 0.4% for Native American participants, compared to nearly 90% for White participants. Only 4.2% of trials conducted subgroup analysis by race or ethnicity, and none reported detailed outcome differences. Terminology varied widely and no trials acknowledged underrepresentation or proposed corrective strategies. Notably, these patterns showed little to no improvement over time.</p><p><strong>Conclusions and implications: </strong>Racial and ethnic minoritized populations remain consistently underreported and underrepresented in Phase III AD trials in the US, limiting the generalizability of findings and risking the exacerbation of health inequities. Improving equity in AD research will require standardized reporting, inclusive recruitment practices, and intentional efforts to engage underrepresented communities.</p>","PeriodicalId":94281,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083570/pdf/","citationCount":"0","resultStr":"{\"title\":\"Racial and Ethnic Reporting and Representation in Phase III Alzheimer's Disease Clinical Trials in the US.\",\"authors\":\"Zhuoer Lin, Ruochen Sun, Joseph S Ross, Kien Lau, Sophia Stumpf, Xi Chen\",\"doi\":\"10.1101/2025.05.03.25326933\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alzheimer's disease (AD) disproportionately affects racial and ethnic minoritized populations in the United States, yet these groups remain markedly underrepresented in clinical research. Phase III clinical trials are critical for informing regulatory decision and treatment guidelines, but the extent to which they report and include racial and ethnic diverse participants in the US context has not been systematically assessed.</p><p><strong>Methods: </strong>We conducted a comprehensive retrospective review of all US-based Phase III AD clinical trials from 1997 to 2023 using the Trialtrove database, cross-referenced with PubMed, ClinicalTrials.gov, and other public sources. We analyzed long-term trends in the reporting and representation of racial and ethnic groups across the longest observation period to date.</p><p><strong>Results: </strong>Of 88 identified trials, 71 (80.7%) had published data. Nearly half (49.3%) did not report any race or ethnicity information. Among those that did, most focused on White patients, with limited and inconsistent reporting for racial and ethnic minoritized groups. Median enrollment was 0.9% for Asian or Pacific Islander, 4.5% for Black (ethnicity unspecified), 7.2% for Black (non-Hispanic), 5.2% for Hispanic, and 0.4% for Native American participants, compared to nearly 90% for White participants. Only 4.2% of trials conducted subgroup analysis by race or ethnicity, and none reported detailed outcome differences. Terminology varied widely and no trials acknowledged underrepresentation or proposed corrective strategies. Notably, these patterns showed little to no improvement over time.</p><p><strong>Conclusions and implications: </strong>Racial and ethnic minoritized populations remain consistently underreported and underrepresented in Phase III AD trials in the US, limiting the generalizability of findings and risking the exacerbation of health inequities. Improving equity in AD research will require standardized reporting, inclusive recruitment practices, and intentional efforts to engage underrepresented communities.</p>\",\"PeriodicalId\":94281,\"journal\":{\"name\":\"medRxiv : the preprint server for health sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083570/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv : the preprint server for health sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2025.05.03.25326933\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.05.03.25326933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:阿尔茨海默病(AD)不成比例地影响美国的种族和少数民族人群,然而这些群体在临床研究中的代表性仍然明显不足。III期临床试验对于监管决策和治疗指南至关重要,但在美国,它们报告的程度以及包括种族和民族不同的参与者的程度尚未得到系统评估。方法:我们使用Trialtrove数据库,交叉引用PubMed、ClinicalTrials.gov和其他公共资源,对1997年至2023年在美国进行的所有III期AD临床试验进行了全面的回顾性评价。在迄今为止最长的观察期内,我们分析了种族和族裔群体的报告和代表性的长期趋势。结果:88项试验中,71项(80.7%)已发表数据。近一半(49.3%)没有报告任何种族或民族信息。在这些研究中,大多数集中在白人患者身上,对种族和少数民族群体的报道有限且不一致。亚裔或太平洋岛民的中位入组率为0.9%,黑人(种族未确定)为4.5%,黑人(非西班牙裔)为7.2%,西班牙裔为5.2%,美洲原住民为0.4%,而白人参与者的中位入组率接近90%。只有4.2%的试验按种族或民族进行了亚组分析,没有报告详细的结果差异。术语差异很大,没有试验承认代表性不足或提出纠正策略。值得注意的是,随着时间的推移,这些模式几乎没有任何改善。结论和意义:在美国的AD III期试验中,种族和少数民族人群的报告和代表性一直偏低,这限制了研究结果的普遍性,并有加剧卫生不平等的风险。提高AD研究的公平性需要标准化的报告、包容性的招聘实践以及有意地让代表性不足的社区参与进来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Racial and Ethnic Reporting and Representation in Phase III Alzheimer's Disease Clinical Trials in the US.

Background: Alzheimer's disease (AD) disproportionately affects racial and ethnic minoritized populations in the United States, yet these groups remain markedly underrepresented in clinical research. Phase III clinical trials are critical for informing regulatory decision and treatment guidelines, but the extent to which they report and include racial and ethnic diverse participants in the US context has not been systematically assessed.

Methods: We conducted a comprehensive retrospective review of all US-based Phase III AD clinical trials from 1997 to 2023 using the Trialtrove database, cross-referenced with PubMed, ClinicalTrials.gov, and other public sources. We analyzed long-term trends in the reporting and representation of racial and ethnic groups across the longest observation period to date.

Results: Of 88 identified trials, 71 (80.7%) had published data. Nearly half (49.3%) did not report any race or ethnicity information. Among those that did, most focused on White patients, with limited and inconsistent reporting for racial and ethnic minoritized groups. Median enrollment was 0.9% for Asian or Pacific Islander, 4.5% for Black (ethnicity unspecified), 7.2% for Black (non-Hispanic), 5.2% for Hispanic, and 0.4% for Native American participants, compared to nearly 90% for White participants. Only 4.2% of trials conducted subgroup analysis by race or ethnicity, and none reported detailed outcome differences. Terminology varied widely and no trials acknowledged underrepresentation or proposed corrective strategies. Notably, these patterns showed little to no improvement over time.

Conclusions and implications: Racial and ethnic minoritized populations remain consistently underreported and underrepresented in Phase III AD trials in the US, limiting the generalizability of findings and risking the exacerbation of health inequities. Improving equity in AD research will require standardized reporting, inclusive recruitment practices, and intentional efforts to engage underrepresented communities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信